Regulus Therapeutics Inc. (NASDAQ:RGLS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
The 2017 Annual Meeting of Stockholders (the Annual Meeting) of
Regulus Therapeutics Inc. (the Company) was held on June1, 2017.
As of April4, 2017, the record date for the Annual Meeting,
53,182,330 shares of common stock were issued and outstanding.A
summary of the matters voted upon at the Annual Meeting and the
final voting results are set forth below.
Proposal 1. Election of Directors
The seven persons listed below were elected as directors at the
Annual Meeting, each to serve until the Companys 2018 Annual
Meeting of Stockholders and until their respective successors are
duly elected and qualified. The final voting results were as
follows:
| Votes For | VotesWithheld | BrokerNon-Votes | ||||||||||
|
David Baltimore, Ph.D. |
16,851,413 | 307,416 | 17,940,021 | |||||||||
|
Mark G. Foletta |
16,746,641 | 412,188 | 17,940,021 | |||||||||
|
Joseph P. Hagan(1) |
5,561,028 | 11,597,801 | 17,940,021 | |||||||||
|
Stelios Papadopoulos, Ph.D. |
16,765,314 | 393,515 | 17,940,021 | |||||||||
|
William Rastetter, Ph.D. |
16,755,703 | 403,126 | 17,940,021 | |||||||||
|
Hugh Rosen, M.D., Ph.D. |
16,860,028 | 298,801 | 17,940,021 | |||||||||
|
Pascale Witz |
16,921,605 | 237,224 | 17,940,021 |
| (1) |
As previously announced and communicated to the Companys stockholders as of the record date for the Annual Meeting, PaulC. Grint, M.D. was previously nominated for election as a director at the Annual Meeting but withdrew himself as a nominee in connection with his resignation as the Companys President and Chief Executive Officer and as a director on May4, 2017. The Companys Board of Directors designated Mr. Hagan, the Companys newly appointed President and Chief Executive Officer and director, as a substitute director nominee for election at the Annual Meeting. All shares represented at the Annual Meeting by valid proxies that were voted in favor of Dr.Grint were voted in favor of the election of Mr. Hagan as substitute nominee. |
Proposal 2. Ratification of the Selection of Independent
Registered Public Accounting Firm
The Companys stockholders ratified the selection by the Companys
Audit Committee of the Board of Directors of Ernst Young LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017. The final voting results
were as follows:
| Votes For | Votes Against | Abstentions | ||
|
34,353,566 |
563,343 | 181,941 |
About Regulus Therapeutics Inc. (NASDAQ:RGLS)
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107. Regulus Therapeutics Inc. (NASDAQ:RGLS) Recent Trading Information
Regulus Therapeutics Inc. (NASDAQ:RGLS) closed its last trading session up +0.15 at 1.60 with 139,888 shares trading hands.
